This page has only limited features, please log in for full access.

Dr. Sherif M. Badawy
1. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA

Basic Info


Research Keywords & Expertise

0 EHealth
0 Medication Adherence
0 mHealth
0 Health-related quality of life
0 patient-reported outcomes

Fingerprints

Medication Adherence
mHealth
Health-related quality of life
patient-reported outcomes
Chronic health conditions
Health services and outcomes research
Patient-centered research
EHealth
digital interventions

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Letter to the editor
Published: 31 July 2021 in Pediatric Blood & Cancer
Reads 0
Downloads 0
ACS Style

Maggie D. Seblani; Susanna A. McColley; Shunyou Gong; Lee M. Bass; Sherif M. Badawy. Pancytopenia in a child with cystic fibrosis and severe copper deficiency: Insight from bone marrow evaluation. Pediatric Blood & Cancer 2021, e29276 .

AMA Style

Maggie D. Seblani, Susanna A. McColley, Shunyou Gong, Lee M. Bass, Sherif M. Badawy. Pancytopenia in a child with cystic fibrosis and severe copper deficiency: Insight from bone marrow evaluation. Pediatric Blood & Cancer. 2021; ():e29276.

Chicago/Turabian Style

Maggie D. Seblani; Susanna A. McColley; Shunyou Gong; Lee M. Bass; Sherif M. Badawy. 2021. "Pancytopenia in a child with cystic fibrosis and severe copper deficiency: Insight from bone marrow evaluation." Pediatric Blood & Cancer , no. : e29276.

Review
Published: 08 July 2021 in JMIR mHealth and uHealth
Reads 0
Downloads 0

Background Telemedicine, including video-, web-, and telephone-based interventions, is used in adult and pediatric populations to deliver health care and communicate with patients. In the realm of hematology, telemedicine has recently been used to safely and efficiently monitor treatment side-effects, perform consultations, and broaden the reach of subspecialty care. Objective We aimed to synthesize and analyze information regarding the feasibility, acceptability, and potential benefits of telemedicine interventions in malignant and nonmalignant hematology, as well as assess the recognized limitations of these interventions. Methods Studies were identified through a comprehensive Medical Subject Headings (MeSH) search on the PubMed MEDLINE, Controlled Register of Clinical Trials (Cochrane CENTRAL from Wiley), Embase, and CINAHL (EBSCO) databases on February 7, 2018. A second search, utilizing the same search strategy, was performed on October 1, 2020. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in the reporting of included evidence. Included studies were original articles researching the feasibility, acceptability, and clinical outcomes of telemedicine or telehealth interventions in pediatric or adult populations with malignant or nonmalignant hematological conditions. Data items in the extraction form included first author name, publication year, country, malignant or nonmalignant hematological condition or disease focus of the study, participant age, participant age subgroup (pediatric or adult), study design and setting, telemedicine intervention type and description, study purpose, and main study outcomes. Results A total of 32 articles met the preset criteria and were included in this study. Most (25/32) studies were conducted in adults, and the remaining (7/32) were conducted in the pediatric population. Of the 32 studies, 12 studied malignant hematological conditions, 18 studied nonmalignant conditions, and two studied both malignant and nonmalignant conditions. Study types included pilot study (11/32), retrospective study (9/32), randomized controlled trial (6/32), cross-sectional study (2/32), case study (1/32), pre-post study (1/32), noncomparative prospective study (1/32), and prospective cohort study (1/32). The three main types of telemedicine interventions utilized across all studies were video-based (9/32), telephone-based (9/32), and web-based interventions (14/32). Study results showed comparable outcomes between telemedicine and traditional patient encounter groups across both pediatric and adult populations for malignant and nonmalignant hematological conditions. Conclusions Evidence from this review suggests that telemedicine use in nonmalignant and malignant hematology provides similar or improved health care compared to face-to-face encounters in both pediatric and adult populations. Telemedicine interventions utilized in the included studies were well received in both pediatric and adult settings. However, more research is needed to determine the efficacy of implementing more widespread use of telemedicine for hematological conditions.

ACS Style

Aashaka C Shah; Linda C O’Dwyer; Sherif M Badawy. Telemedicine in Malignant and Nonmalignant Hematology: Systematic Review of Pediatric and Adult Studies. JMIR mHealth and uHealth 2021, 9, e29619 .

AMA Style

Aashaka C Shah, Linda C O’Dwyer, Sherif M Badawy. Telemedicine in Malignant and Nonmalignant Hematology: Systematic Review of Pediatric and Adult Studies. JMIR mHealth and uHealth. 2021; 9 (7):e29619.

Chicago/Turabian Style

Aashaka C Shah; Linda C O’Dwyer; Sherif M Badawy. 2021. "Telemedicine in Malignant and Nonmalignant Hematology: Systematic Review of Pediatric and Adult Studies." JMIR mHealth and uHealth 9, no. 7: e29619.

Commentary
Published: 10 June 2021 in Journal of Cardiovascular Development and Disease
Reads 0
Downloads 0

Society and medical practice have been restructured dramatically to avoid further spread of the COVID-19 virus; telehealth/telemedicine, mask wearing, and nationwide social distancing practices have become widespread. However, we still face unprecedented challenges in fields where patients require frequent and active follow-up visits for monitoring, including that of solid-organ transplant, and in particular, heart transplant. Adherence to immunosuppression remains a unique challenge in heart transplantation, especially during the COVID-19 pandemic. Failure to adhere to immunosuppression can have disastrous consequences, including graft rejection and death. In this article, we discuss challenges related to adherence to immunosuppression medications among heart transplant recipients, as well as opportunities to leverage digital approaches and interventions to monitor and optimize adherence behavior and health outcomes in this population.

ACS Style

Tasmeen Hussain; Keira Nassetta; Sherif Badawy. Adherence to Immunosuppression Medications among Heart Transplant Recipients: Challenges, Opportunities, and Potential Role of Digital Approaches in the COVID-19 Era. Journal of Cardiovascular Development and Disease 2021, 8, 68 .

AMA Style

Tasmeen Hussain, Keira Nassetta, Sherif Badawy. Adherence to Immunosuppression Medications among Heart Transplant Recipients: Challenges, Opportunities, and Potential Role of Digital Approaches in the COVID-19 Era. Journal of Cardiovascular Development and Disease. 2021; 8 (6):68.

Chicago/Turabian Style

Tasmeen Hussain; Keira Nassetta; Sherif Badawy. 2021. "Adherence to Immunosuppression Medications among Heart Transplant Recipients: Challenges, Opportunities, and Potential Role of Digital Approaches in the COVID-19 Era." Journal of Cardiovascular Development and Disease 8, no. 6: 68.

Special report
Published: 28 May 2021 in Pediatric Blood & Cancer
Reads 0
Downloads 0

Choosing Wisely is a medical stewardship and quality-improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The American Society of Hematology (ASH) has been an active participant in the Choosing Wisely project. In 2019, ASH and the American Society of Pediatric Hematology/Oncology (ASPHO) formed a joint task force to solicit, evaluate, and select items for a pediatric-focused Choosing Wisely list. By using an iterative process and an evidence-based method, the ASH-ASPHO Task Force identified 5 hematologic tests and treatments that health care providers and patients should question because they are not supported by evidence, and/or they involve risks of medical and financial costs with low likelihood of benefit. The ASH-ASPHO Choosing Wisely recommendations are as follows: (1) avoid routine preoperative hemostatic testing in an otherwise healthy child with no previous personal or family history of bleeding, (2) avoid platelet transfusion in asymptomatic children with a platelet count >103/μL unless an invasive procedure is planned, (3) avoid thrombophilia testing in children with venous access-associated thrombosis and no positive family history, (4) avoid packed red blood cells transfusion for asymptomatic children with iron deficiency anemia and no active bleeding, and (5) avoid routine administration of granulocyte colony-stimulating factor for prophylaxis of children with asymptomatic autoimmune neutropenia and no history of recurrent or severe infections. We recommend that health care providers carefully consider the anticipated risks and benefits of these identified tests and treatments before performing them.

ACS Style

Sarah H. O'Brien; Sherif M. Badawy; Seth J. Rotz; Mona D. Shah; Julie Makarski; Rachel S. Bercovitz; Mary‐Jane S. Hogan; Lori Luchtman‐Jones; Julie A. Panepinto; Ginna M. Priola; Char M. Witmer; Julie A. Wolfson; Marianne Yee; Lisa K. Hicks. The ASH‐ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. Pediatric Blood & Cancer 2021, 68, e28967 .

AMA Style

Sarah H. O'Brien, Sherif M. Badawy, Seth J. Rotz, Mona D. Shah, Julie Makarski, Rachel S. Bercovitz, Mary‐Jane S. Hogan, Lori Luchtman‐Jones, Julie A. Panepinto, Ginna M. Priola, Char M. Witmer, Julie A. Wolfson, Marianne Yee, Lisa K. Hicks. The ASH‐ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. Pediatric Blood & Cancer. 2021; 68 (8):e28967.

Chicago/Turabian Style

Sarah H. O'Brien; Sherif M. Badawy; Seth J. Rotz; Mona D. Shah; Julie Makarski; Rachel S. Bercovitz; Mary‐Jane S. Hogan; Lori Luchtman‐Jones; Julie A. Panepinto; Ginna M. Priola; Char M. Witmer; Julie A. Wolfson; Marianne Yee; Lisa K. Hicks. 2021. "The ASH‐ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question." Pediatric Blood & Cancer 68, no. 8: e28967.

Report
Published: 24 May 2021 in Pediatric Hematology and Oncology
Reads 0
Downloads 0

Infertility secondary to chemotherapy, myeloablative conditioning regimens prior to stem cell transplantation, radiation therapy, and/or surgery is an important cause of morbidity and psychosocial distress among pediatric cancer patients. Known options exist for fertility preservation; however, knowledge among providers varies. We conducted a pilot study with an educational intervention over one-hour for hematology-oncology faculty, fellows, and advanced practice providers. Participants completed pre-/post-test assessment on fertility preservation knowledge. Participants’ pretest mean (SD) score was 53% (17%), which significantly increased to 72% (11%) in the post-test (p = 0.0004). We demonstrated that a fertility education intervention could improve knowledge regarding infertility risk assessment and fertility preservation options.

ACS Style

Kristiyana Kaneva; Laura Erickson; Erin Rowell; Sherif M. Badawy. Fertility preservation education for pediatric hematology-oncology fellows, faculty and advanced practice providers: a pilot study. Pediatric Hematology and Oncology 2021, 1 -6.

AMA Style

Kristiyana Kaneva, Laura Erickson, Erin Rowell, Sherif M. Badawy. Fertility preservation education for pediatric hematology-oncology fellows, faculty and advanced practice providers: a pilot study. Pediatric Hematology and Oncology. 2021; ():1-6.

Chicago/Turabian Style

Kristiyana Kaneva; Laura Erickson; Erin Rowell; Sherif M. Badawy. 2021. "Fertility preservation education for pediatric hematology-oncology fellows, faculty and advanced practice providers: a pilot study." Pediatric Hematology and Oncology , no. : 1-6.

Journal article
Published: 21 May 2021 in JMIR Research Protocols
Reads 0
Downloads 0

Background Sickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications, early morbidity and mortality, and high health care utilization. Until recently, hydroxyurea was the only disease-modifying treatment for this life-threatening disease and has remained the only option for children younger than 5 years. Evidence-based guidelines recommend using a shared decision-making (SDM) approach for offering hydroxyurea to children with SCA (HbSS or HbS/β0 thalassemia) aged as early as 9 months. However, the uptake remains suboptimal, likely because caregivers lack information about hydroxyurea and have concerns about its safety and potential long-term side effects. Moreover, clinicians do not routinely receive training or tools, especially those that provide medical evidence and consider caregivers’ preferences and values, to facilitate a shared discussion with caregivers. Objective The aim of this study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that considers medical evidence and parent values and preferences). Methods We designed our study to compare the effectiveness of two methods for disseminating hydroxyurea guidelines to facilitate SDM: a clinician pocket guide (ie, usual care) and a clinician hydroxyurea SDM toolkit (H-SDM toolkit). Our primary outcomes are caregiver reports of decisional uncertainty and knowledge of hydroxyurea. The study also assesses the number of children (aged 0-5 years) who were offered and prescribed hydroxyurea and the resultant health outcomes. Results The Ethics Committee of the Cincinnati Children’s Hospital Medical Center approved this study in November 2017. As of February 2021, we have enrolled 120 caregiver participants. Conclusions The long-term objective of this study is to improve the quality of care for children with SCA. Using multicomponent dissemination methods developed in partnership with key stakeholders and designed to address barriers to high-quality care, caregivers of patients with SCA can make informed and shared decisions about their health. Trial Registration ClinicalTrials.gov NCT03442114; https://clinicaltrials.gov/ct2/show/NCT03442114 International Registered Report Identifier (IRRID) DERR1-10.2196/27650

ACS Style

Anna M Hood; Heather Strong; Cara Nwankwo; Yolanda Johnson; James Peugh; Constance A Mara; Lisa M Shook; William B Brinkman; Francis J Real; Melissa D Klein; Rogelle Hackworth; Sherif M Badawy; Alexis A Thompson; Jean L Raphael; Amber M Yates; Kim Smith-Whitley; Allison A King; Cecelia Calhoun; Susan E Creary; Connie M Piccone; Aimee K Hildenbrand; Steven K Reader; Lynne Neumayr; Emily R Meier; Amy E Sobota; Sohail Rana; Maria Britto; Kay L Saving; Marsha Treadwell; Charles T Quinn; Russell E Ware; Lori E Crosby. Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols 2021, 10, e27650 .

AMA Style

Anna M Hood, Heather Strong, Cara Nwankwo, Yolanda Johnson, James Peugh, Constance A Mara, Lisa M Shook, William B Brinkman, Francis J Real, Melissa D Klein, Rogelle Hackworth, Sherif M Badawy, Alexis A Thompson, Jean L Raphael, Amber M Yates, Kim Smith-Whitley, Allison A King, Cecelia Calhoun, Susan E Creary, Connie M Piccone, Aimee K Hildenbrand, Steven K Reader, Lynne Neumayr, Emily R Meier, Amy E Sobota, Sohail Rana, Maria Britto, Kay L Saving, Marsha Treadwell, Charles T Quinn, Russell E Ware, Lori E Crosby. Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols. 2021; 10 (5):e27650.

Chicago/Turabian Style

Anna M Hood; Heather Strong; Cara Nwankwo; Yolanda Johnson; James Peugh; Constance A Mara; Lisa M Shook; William B Brinkman; Francis J Real; Melissa D Klein; Rogelle Hackworth; Sherif M Badawy; Alexis A Thompson; Jean L Raphael; Amber M Yates; Kim Smith-Whitley; Allison A King; Cecelia Calhoun; Susan E Creary; Connie M Piccone; Aimee K Hildenbrand; Steven K Reader; Lynne Neumayr; Emily R Meier; Amy E Sobota; Sohail Rana; Maria Britto; Kay L Saving; Marsha Treadwell; Charles T Quinn; Russell E Ware; Lori E Crosby. 2021. "Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial." JMIR Research Protocols 10, no. 5: e27650.

Journal article
Published: 14 May 2021 in JMIR Research Protocols
Reads 0
Downloads 0

Background Patients with sickle cell disease (SCD) experience significant medical and psychological stressors that affect their mental health, well-being, and disease outcomes. Digital cognitive behavioral therapy (CBT) has been used in other patient populations and has demonstrated clinical benefits. Although evidence-based, nonpharmacological interventions for pain management are widely used in other populations, these treatments have not been well studied in SCD. Currently, there are no adequately powered large-scale clinical trials to evaluate the effectiveness and dissemination potential of behavioral pain management for adults with SCD. Furthermore, some important details regarding behavioral therapies in SCD remain unclear—in particular, what works best for whom and when. Objective Our primary goal is to compare the effectiveness of two smartphone–delivered programs for reducing SCD pain symptoms: digital CBT versus pain and SCD education (Education). Our secondary goal is to assess whether baseline depression symptoms moderate the effect of interventions on pain outcomes. We hypothesize that digital CBT will confer greater benefits on pain outcomes and depressive symptoms at 6 months and a greater reduction in health care use (eg, opioid prescriptions or refills or acute care visits) over 12 months. Methods The CaRISMA (Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications) study is a multisite comparative effectiveness trial funded by the Patient-Centered Outcomes Research Institute. CaRISMA is conducted at six clinical academic sites, in partnership with four community-based organizations. CaRISMA will evaluate the effectiveness of two 12-week health coach–supported digital health programs with a total of 350 participants in two groups: CBT (n=175) and Education (n=175). Participants will complete a series of questionnaires at baseline and at 3, 6, and 12 months. The primary outcome will be the change in pain interference between the study arms. We will also evaluate changes in pain intensity, depressive symptoms, other patient-reported outcomes, and health care use as secondary outcomes. We have 80% power to detect a difference of 0.37 SDs between study arms on 6-month changes in the outcomes with 15% expected attrition at 6 months. An exploratory analysis will examine whether baseline depression symptoms moderate the effect of the intervention on pain interference. Results This study will be conducted from March 2021 through February 2022, with results expected to be available in February 2023. Conclusions Patients with SCD experience significant disease burden, psychosocial stress, and impairment of their quality of life. CaRISMA proposes to leverage digital technology and overcome barriers to the routine use of behavioral treatments for pain and depressive symptoms in the treatment of adults with SCD. The study will provide data on the comparative effectiveness of digital CBT and Education approaches and evaluate the potential for implementing evidence-based behavioral interventions to manage SCD pain. Trial Registration ClinicalTrials.gov NCT04419168; https://clinicaltrials.gov/ct2/show/NCT04419168. International Registered Report Identifier (IRRID) PRR1-10.2196/29014

ACS Style

Sherif M Badawy; Kaleab Z Abebe; Charlotte A Reichman; Grace Checo; Megan E Hamm; Jennifer Stinson; Chitra Lalloo; Patrick Carroll; Santosh L Saraf; Victor R Gordeuk; Payal Desai; Nirmish Shah; Darla Liles; Cassandra Trimnell; Charles R Jonassaint. Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study. JMIR Research Protocols 2021, 10, e29014 .

AMA Style

Sherif M Badawy, Kaleab Z Abebe, Charlotte A Reichman, Grace Checo, Megan E Hamm, Jennifer Stinson, Chitra Lalloo, Patrick Carroll, Santosh L Saraf, Victor R Gordeuk, Payal Desai, Nirmish Shah, Darla Liles, Cassandra Trimnell, Charles R Jonassaint. Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study. JMIR Research Protocols. 2021; 10 (5):e29014.

Chicago/Turabian Style

Sherif M Badawy; Kaleab Z Abebe; Charlotte A Reichman; Grace Checo; Megan E Hamm; Jennifer Stinson; Chitra Lalloo; Patrick Carroll; Santosh L Saraf; Victor R Gordeuk; Payal Desai; Nirmish Shah; Darla Liles; Cassandra Trimnell; Charles R Jonassaint. 2021. "Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study." JMIR Research Protocols 10, no. 5: e29014.

Article
Published: 27 April 2021 in Cochrane Database of Systematic Reviews
Reads 0
Downloads 0

Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To identify and assess the effects of digital behavioural interventions focused on behavioural change in people with SCD on: medication adherence or disease management (such as managing acute and chronic pain), or both, on health‐ and other‐related outcomes; specific subgroups defined by age (i.e. children, adolescents and adults) and type of modality or delivery (e.g. cell phone, the Internet).

ACS Style

Sherif M Badawy; Robert M Cronin; Robert I Liem; Tonya M Palermo. Digital behavioural interventions for people with sickle cell disease. Cochrane Database of Systematic Reviews 2021, 1 .

AMA Style

Sherif M Badawy, Robert M Cronin, Robert I Liem, Tonya M Palermo. Digital behavioural interventions for people with sickle cell disease. Cochrane Database of Systematic Reviews. 2021; (4):1.

Chicago/Turabian Style

Sherif M Badawy; Robert M Cronin; Robert I Liem; Tonya M Palermo. 2021. "Digital behavioural interventions for people with sickle cell disease." Cochrane Database of Systematic Reviews , no. 4: 1.

Letter to the editor
Published: 21 April 2021 in Pediatric Blood & Cancer
Reads 0
Downloads 0
ACS Style

Zoe I. Listernick; Lauren Knight; Hannah J. Elkus; Rachel S. Bercovitz; Shunyou Gong; Sherif M. Badawy. Scurvy and non‐immune hemolytic anemia in an adolescent with trisomy 21. Pediatric Blood & Cancer 2021, 68, e29070 .

AMA Style

Zoe I. Listernick, Lauren Knight, Hannah J. Elkus, Rachel S. Bercovitz, Shunyou Gong, Sherif M. Badawy. Scurvy and non‐immune hemolytic anemia in an adolescent with trisomy 21. Pediatric Blood & Cancer. 2021; 68 (8):e29070.

Chicago/Turabian Style

Zoe I. Listernick; Lauren Knight; Hannah J. Elkus; Rachel S. Bercovitz; Shunyou Gong; Sherif M. Badawy. 2021. "Scurvy and non‐immune hemolytic anemia in an adolescent with trisomy 21." Pediatric Blood & Cancer 68, no. 8: e29070.

Review
Published: 14 April 2021
Reads 0
Downloads 0

BACKGROUND Telemedicine, including video-, web-, and telephone-based interventions, is used in adult and pediatric populations to deliver health care and communicate with patients. In the realm of hematology, telemedicine has recently been used to safely and efficiently monitor treatment side-effects, perform consultations, and broaden the reach of subspecialty care. OBJECTIVE We aimed to synthesize and analyze information regarding the feasibility, acceptability, and potential benefits of telemedicine interventions in malignant and nonmalignant hematology, as well as assess the recognized limitations of these interventions. METHODS Studies were identified through a comprehensive Medical Subject Headings (MeSH) search on the PubMed MEDLINE, Controlled Register of Clinical Trials (Cochrane CENTRAL from Wiley), Embase, and CINAHL (EBSCO) databases on February 7, 2018. A second search, utilizing the same search strategy, was performed on October 1, 2020. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in the reporting of included evidence. Included studies were original articles researching the feasibility, acceptability, and clinical outcomes of telemedicine or telehealth interventions in pediatric or adult populations with malignant or nonmalignant hematological conditions. Data items in the extraction form included first author name, publication year, country, malignant or nonmalignant hematological condition or disease focus of the study, participant age, participant age subgroup (pediatric or adult), study design and setting, telemedicine intervention type and description, study purpose, and main study outcomes. RESULTS A total of 32 articles met the preset criteria and were included in this study. Most (25/32) studies were conducted in adults, and the remaining (7/32) were conducted in the pediatric population. Of the 32 studies, 12 studied malignant hematological conditions, 18 studied nonmalignant conditions, and two studied both malignant and nonmalignant conditions. Study types included pilot study (11/32), retrospective study (9/32), randomized controlled trial (6/32), cross-sectional study (2/32), case study (1/32), pre-post study (1/32), noncomparative prospective study (1/32), and prospective cohort study (1/32). The three main types of telemedicine interventions utilized across all studies were video-based (9/32), telephone-based (9/32), and web-based interventions (14/32). Study results showed comparable outcomes between telemedicine and traditional patient encounter groups across both pediatric and adult populations for malignant and nonmalignant hematological conditions. CONCLUSIONS Evidence from this review suggests that telemedicine use in nonmalignant and malignant hematology provides similar or improved health care compared to face-to-face encounters in both pediatric and adult populations. Telemedicine interventions utilized in the included studies were well received in both pediatric and adult settings. However, more research is needed to determine the efficacy of implementing more widespread use of telemedicine for hematological conditions.

ACS Style

Aashaka C Shah; Linda C O’Dwyer; Sherif M Badawy. Telemedicine in Malignant and Nonmalignant Hematology: Systematic Review of Pediatric and Adult Studies (Preprint). 2021, 1 .

AMA Style

Aashaka C Shah, Linda C O’Dwyer, Sherif M Badawy. Telemedicine in Malignant and Nonmalignant Hematology: Systematic Review of Pediatric and Adult Studies (Preprint). . 2021; ():1.

Chicago/Turabian Style

Aashaka C Shah; Linda C O’Dwyer; Sherif M Badawy. 2021. "Telemedicine in Malignant and Nonmalignant Hematology: Systematic Review of Pediatric and Adult Studies (Preprint)." , no. : 1.

Preprint content
Published: 24 March 2021
Reads 0
Downloads 0

BACKGROUND Patients with sickle cell disease (SCD) experience significant medical and psychological stressors that affect their mental health, well-being, and disease outcomes. Digital cognitive behavioral therapy (CBT) has been used in other patient populations and has demonstrated clinical benefits. Although evidence-based, nonpharmacological interventions for pain management are widely used in other populations, these treatments have not been well studied in SCD. Currently, there are no adequately powered large-scale clinical trials to evaluate the effectiveness and dissemination potential of behavioral pain management for adults with SCD. Furthermore, some important details regarding behavioral therapies in SCD remain unclear—in particular, what works best for whom and when. OBJECTIVE Our primary goal is to compare the effectiveness of two smartphone–delivered programs for reducing SCD pain symptoms: digital CBT versus pain and SCD education (Education). Our secondary goal is to assess whether baseline depression symptoms moderate the effect of interventions on pain outcomes. We hypothesize that digital CBT will confer greater benefits on pain outcomes and depressive symptoms at 6 months and a greater reduction in health care use (eg, opioid prescriptions or refills or acute care visits) over 12 months. METHODS The CaRISMA (Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications) study is a multisite comparative effectiveness trial funded by the Patient-Centered Outcomes Research Institute. CaRISMA is conducted at six clinical academic sites, in partnership with four community-based organizations. CaRISMA will evaluate the effectiveness of two 12-week health coach–supported digital health programs with a total of 350 participants in two groups: CBT (n=175) and Education (n=175). Participants will complete a series of questionnaires at baseline and at 3, 6, and 12 months. The primary outcome will be the change in pain interference between the study arms. We will also evaluate changes in pain intensity, depressive symptoms, other patient-reported outcomes, and health care use as secondary outcomes. We have 80% power to detect a difference of 0.37 SDs between study arms on 6-month changes in the outcomes with 15% expected attrition at 6 months. An exploratory analysis will examine whether baseline depression symptoms moderate the effect of the intervention on pain interference. RESULTS This study will be conducted from March 2021 through February 2022, with results expected to be available in February 2023. CONCLUSIONS Patients with SCD experience significant disease burden, psychosocial stress, and impairment of their quality of life. CaRISMA proposes to leverage digital technology and overcome barriers to the routine use of behavioral treatments for pain and depressive symptoms in the treatment of adults with SCD. The study will provide data on the comparative effectiveness of digital CBT and Education approaches and evaluate the potential for implementing evidence-based behavioral interventions to manage SCD pain. CLINICALTRIAL ClinicalTrials.gov NCT04419168; https://clinicaltrials.gov/ct2/show/NCT04419168. INTERNATIONAL REGISTERED REPORT PRR1-10.2196/29014

ACS Style

Sherif M Badawy; Kaleab Z Abebe; Charlotte A Reichman; Grace Checo; Megan E Hamm; Jennifer Stinson; Chitra Lalloo; Patrick Carroll; Santosh L Saraf; Victor R Gordeuk; Payal Desai; Nirmish Shah; Darla Liles; Cassandra Trimnell; Charles R Jonassaint. Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study (Preprint). 2021, 1 .

AMA Style

Sherif M Badawy, Kaleab Z Abebe, Charlotte A Reichman, Grace Checo, Megan E Hamm, Jennifer Stinson, Chitra Lalloo, Patrick Carroll, Santosh L Saraf, Victor R Gordeuk, Payal Desai, Nirmish Shah, Darla Liles, Cassandra Trimnell, Charles R Jonassaint. Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study (Preprint). . 2021; ():1.

Chicago/Turabian Style

Sherif M Badawy; Kaleab Z Abebe; Charlotte A Reichman; Grace Checo; Megan E Hamm; Jennifer Stinson; Chitra Lalloo; Patrick Carroll; Santosh L Saraf; Victor R Gordeuk; Payal Desai; Nirmish Shah; Darla Liles; Cassandra Trimnell; Charles R Jonassaint. 2021. "Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study (Preprint)." , no. : 1.

Review
Published: 24 February 2021 in JMIR Pediatrics and Parenting
Reads 0
Downloads 0

Background Telemedicine modalities, such as videoconferencing, are used by health care providers to remotely deliver health care to patients. Telemedicine use in pediatrics has increased in recent years. This has resulted in improved health care access, optimized disease management, progress in the monitoring of health conditions, and fewer exposures to patients with illnesses during pandemics (eg, the COVID-19 pandemic). Objective We aimed to systematically evaluate the most recent evidence on the feasibility and accessibility of telemedicine services, patients’ and care providers’ satisfaction with these services, and treatment outcomes related to telemedicine service use among pediatric populations with different health conditions. Methods Studies were obtained from the PubMed database on May 10, 2020. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. In this review, we included randomized controlled trials from the last 10 years that used a telemedicine approach as a study intervention or assessed telemedicine as a subspecialty of pediatric care. Titles and abstracts were independently screened based on the eligibility criteria. Afterward, full texts were retrieved and independently screened based on the eligibility criteria. A standardized form was used to extract the following data: publication title, first author’s name, publication year, participants’ characteristics, study design, the technology-based approach that was used, intervention characteristics, study goals, and study findings. Results In total, 11 articles met the inclusion criteria and were included in this review. All studies were categorized as randomized controlled trials (8/11, 73%) or cluster randomized trials (3/11, 27%). The number of participants in each study ranged from 22 to 400. The health conditions that were assessed included obesity (3/11, 27%), asthma (2/11, 18%), mental health conditions (1/11, 9%), otitis media (1/11, 9%), skin conditions (1/11, 9%), type 1 diabetes (1/11, 9%), attention deficit hyperactivity disorder (1/11, 9%), and cystic fibrosis–related pancreatic insufficiency (1/11). The telemedicine approaches that were used included patient and doctor videoconferencing visits (5/11, 45%), smartphone-based interventions (3/11, 27%), telephone counseling (2/11, 18%), and telemedicine-based screening visits (1/11, 9%). The telemedicine interventions in all included studies resulted in outcomes that were comparable to or better than the outcomes of control groups. These outcomes were related to symptom management, quality of life, satisfaction, medication adherence, visit completion rates, and disease progression. Conclusions Although more research is needed, the evidence from this review suggests that telemedicine services for the general public and pediatric care are comparable to or better than in-person services. Patients, health care professionals, and caregivers may benefit from using both telemedicine services and traditional, in-person health care services. To maximize the potential of telemedicine, future research should focus on improving patients’ access to care, increasing the cost-effectiveness of telemedicine services, and eliminating barriers to telemedicine use.

ACS Style

Aashaka C Shah; Sherif M Badawy. Telemedicine in Pediatrics: Systematic Review of Randomized Controlled Trials. JMIR Pediatrics and Parenting 2021, 4, e22696 .

AMA Style

Aashaka C Shah, Sherif M Badawy. Telemedicine in Pediatrics: Systematic Review of Randomized Controlled Trials. JMIR Pediatrics and Parenting. 2021; 4 (1):e22696.

Chicago/Turabian Style

Aashaka C Shah; Sherif M Badawy. 2021. "Telemedicine in Pediatrics: Systematic Review of Randomized Controlled Trials." JMIR Pediatrics and Parenting 4, no. 1: e22696.

Journal article
Published: 18 February 2021 in Journal of Medical Internet Research
Reads 0
Downloads 0

Background Suboptimal adherence to 6-mercaptopurine (6-MP) is prevalent in pediatric acute lymphoblastic leukemia (ALL) and associated with increased risk of relapse. Rapid uptake of personal technology makes mobile health (mHealth) an attractive platform to promote adherence. Objective Study objectives were to examine access to mobile technology and preferences for an mHealth intervention to improve medication adherence in pediatric ALL. Methods A cross-sectional survey was administered in oncology clinic to parents of children with ALL as well as adolescents and young adults (AYAs) with ALL receiving maintenance chemotherapy. Results A total of 49 parents (median age [IQR] 39 [33-42] years; female 76% [37/49]) and 15 patients (median age [IQR] 17 [16-19]; male 80% [12/15]) participated. All parents and AYAs owned electronic tablets, smartphones, or both. Parents’ most endorsed mHealth app features included a list of medications (71%, 35/49), information about 6-MP (71%, 35/49), refill reminders (71%, 35/49), and reminders to take 6-MP (71%, 35/49). AYAs' most endorsed features included refill reminders (73%, 11/15), reminders to take 6-MP (73%, 11/15), and tracking 6-MP (73%, 11/15). Conclusions Parents and AYAs reported ubiquitous access to mobile technology and strong interest in multiple adherence-specific mHealth app features. Parents and AYAs provided valuable insight into preferred features for a multifunctional behavioral intervention (mHealth app) to promote medication adherence in pediatric ALL.

ACS Style

Mallorie B Heneghan; Tasmeen Hussain; Leonardo Barrera; Stephanie W Cai; Maureen Haugen; Elaine Morgan; Jenna Rossoff; Joanna Weinstein; Nobuko Hijiya; David Cella; Sherif M Badawy. Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques. Journal of Medical Internet Research 2021, 23, e24893 .

AMA Style

Mallorie B Heneghan, Tasmeen Hussain, Leonardo Barrera, Stephanie W Cai, Maureen Haugen, Elaine Morgan, Jenna Rossoff, Joanna Weinstein, Nobuko Hijiya, David Cella, Sherif M Badawy. Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques. Journal of Medical Internet Research. 2021; 23 (2):e24893.

Chicago/Turabian Style

Mallorie B Heneghan; Tasmeen Hussain; Leonardo Barrera; Stephanie W Cai; Maureen Haugen; Elaine Morgan; Jenna Rossoff; Joanna Weinstein; Nobuko Hijiya; David Cella; Sherif M Badawy. 2021. "Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques." Journal of Medical Internet Research 23, no. 2: e24893.

Letter to the editor
Published: 08 February 2021 in Pediatric Blood & Cancer
Reads 0
Downloads 0
ACS Style

Sherif M. Badawy; Alisa Vasileva; Rukhmi V. Bhat; Shunyou Gong; Robert I. Liem. A case of severe bi‐cytopenias and hypocellular bone marrow with uncontrolled nephropathic cystinosis. Pediatric Blood & Cancer 2021, 68, e28952 .

AMA Style

Sherif M. Badawy, Alisa Vasileva, Rukhmi V. Bhat, Shunyou Gong, Robert I. Liem. A case of severe bi‐cytopenias and hypocellular bone marrow with uncontrolled nephropathic cystinosis. Pediatric Blood & Cancer. 2021; 68 (6):e28952.

Chicago/Turabian Style

Sherif M. Badawy; Alisa Vasileva; Rukhmi V. Bhat; Shunyou Gong; Robert I. Liem. 2021. "A case of severe bi‐cytopenias and hypocellular bone marrow with uncontrolled nephropathic cystinosis." Pediatric Blood & Cancer 68, no. 6: e28952.

Preprint content
Published: 04 February 2021
Reads 0
Downloads 0

BACKGROUND Sickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications, early morbidity and mortality, and high health care utilization. Until recently, hydroxyurea was the only disease-modifying treatment for this life-threatening disease and has remained the only option for children younger than 5 years. Evidence-based guidelines recommend using a shared decision-making (SDM) approach for offering hydroxyurea to children with SCA (HbSS or HbS/β0 thalassemia) aged as early as 9 months. However, the uptake remains suboptimal, likely because caregivers lack information about hydroxyurea and have concerns about its safety and potential long-term side effects. Moreover, clinicians do not routinely receive training or tools, especially those that provide medical evidence and consider caregivers’ preferences and values, to facilitate a shared discussion with caregivers. OBJECTIVE The aim of this study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that considers medical evidence and parent values and preferences). METHODS We designed our study to compare the effectiveness of two methods for disseminating hydroxyurea guidelines to facilitate SDM: a clinician pocket guide (ie, usual care) and a clinician hydroxyurea SDM toolkit (H-SDM toolkit). Our primary outcomes are caregiver reports of decisional uncertainty and knowledge of hydroxyurea. The study also assesses the number of children (aged 0-5 years) who were offered and prescribed hydroxyurea and the resultant health outcomes. RESULTS The Ethics Committee of the Cincinnati Children’s Hospital Medical Center approved this study in November 2017. As of February 2021, we have enrolled 120 caregiver participants. CONCLUSIONS The long-term objective of this study is to improve the quality of care for children with SCA. Using multicomponent dissemination methods developed in partnership with key stakeholders and designed to address barriers to high-quality care, caregivers of patients with SCA can make informed and shared decisions about their health. CLINICALTRIAL ClinicalTrials.gov NCT03442114; https://clinicaltrials.gov/ct2/show/NCT03442114 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/27650

ACS Style

Anna M Hood; Heather Strong; Cara Nwankwo; Yolanda Johnson; James Peugh; Constance A Mara; Lisa M Shook; William B Brinkman; Francis J Real; Melissa D Klein; Rogelle Hackworth; Sherif M Badawy; Alexis A Thompson; Jean L Raphael; Amber M Yates; Kim Smith-Whitley; Allison A King; Cecelia Calhoun; Susan E Creary; Connie M Piccone; Aimee K Hildenbrand; Steven K Reader; Lynne Neumayr; Emily R Meier; Amy E Sobota; Sohail Rana; Maria Britto; Kay L Saving; Marsha Treadwell; Charles T Quinn; Russell E Ware; Lori E Crosby. Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial (Preprint). 2021, 1 .

AMA Style

Anna M Hood, Heather Strong, Cara Nwankwo, Yolanda Johnson, James Peugh, Constance A Mara, Lisa M Shook, William B Brinkman, Francis J Real, Melissa D Klein, Rogelle Hackworth, Sherif M Badawy, Alexis A Thompson, Jean L Raphael, Amber M Yates, Kim Smith-Whitley, Allison A King, Cecelia Calhoun, Susan E Creary, Connie M Piccone, Aimee K Hildenbrand, Steven K Reader, Lynne Neumayr, Emily R Meier, Amy E Sobota, Sohail Rana, Maria Britto, Kay L Saving, Marsha Treadwell, Charles T Quinn, Russell E Ware, Lori E Crosby. Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial (Preprint). . 2021; ():1.

Chicago/Turabian Style

Anna M Hood; Heather Strong; Cara Nwankwo; Yolanda Johnson; James Peugh; Constance A Mara; Lisa M Shook; William B Brinkman; Francis J Real; Melissa D Klein; Rogelle Hackworth; Sherif M Badawy; Alexis A Thompson; Jean L Raphael; Amber M Yates; Kim Smith-Whitley; Allison A King; Cecelia Calhoun; Susan E Creary; Connie M Piccone; Aimee K Hildenbrand; Steven K Reader; Lynne Neumayr; Emily R Meier; Amy E Sobota; Sohail Rana; Maria Britto; Kay L Saving; Marsha Treadwell; Charles T Quinn; Russell E Ware; Lori E Crosby. 2021. "Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial (Preprint)." , no. : 1.

Review
Published: 25 January 2021 in Blood Advances
Reads 0
Downloads 0

Patients with sickle cell disease (SCD) and thalassemia experience several complications across their lifespan that lead to impairment in different health-related quality of life (HRQOL) domains. There is increasing interest in curative therapies for patients with SCD and thalassemia, including hematopoietic stem cell transplant (HSCT) and gene therapy; however, the effect of these therapies on various HRQOL domains remains unclear. Our objective was to systematically evaluate the most recent evidence for the effect of HSCT and gene therapy on HRQOL in patients with SCD and thalassemia. A systematic search of medical literature databases was conducted. A total of 16 studies (thalassemia, n = 9; SCD, n = 6; both, n = 1) involving 517 participants met inclusion criteria (thalassemia, n = 416; SCD, n = 101). HSCT was associated with a small to large positive effects in most HRQOL domains (Cohen’s d; mean = 0.47; median = 0.37; range, 0.27-2.05). In thalassemia, HSCT was frequently associated with large positive effects in physical and emotional HRQOL domains (median d = 0.79 and d = 0.57, respectively). In SCD, HSCT was associated with large positive effects in all HRQOL domains. Emerging data suggest improvement in HRQOL outcomes across different domains following gene therapy in thalassemia and SCD. The quality of evidence was moderate in 13 studies (81%). HSCT has a positive impact on several HRQOL domains in patients with SCD and thalassemia; however, more longitudinal studies are warranted to assess the sustainability of these effects. Reporting HRQOL outcomes from ongoing gene therapy or gene-editing trials in SCD and thalassemia is key to better understand the benefits of such therapies.

ACS Style

Sherif M. Badawy; Usman Beg; Robert I. Liem; Sonali Chaudhury; Alexis A. Thompson. A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Advances 2021, 5, 570 -583.

AMA Style

Sherif M. Badawy, Usman Beg, Robert I. Liem, Sonali Chaudhury, Alexis A. Thompson. A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Advances. 2021; 5 (2):570-583.

Chicago/Turabian Style

Sherif M. Badawy; Usman Beg; Robert I. Liem; Sonali Chaudhury; Alexis A. Thompson. 2021. "A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy." Blood Advances 5, no. 2: 570-583.

Review
Published: 21 November 2020
Reads 0
Downloads 0

BACKGROUND Telemedicine modalities, such as videoconferencing, are used by health care providers to remotely deliver health care to patients. Telemedicine use in pediatrics has increased in recent years. This has resulted in improved health care access, optimized disease management, progress in the monitoring of health conditions, and fewer exposures to patients with illnesses during pandemics (eg, the COVID-19 pandemic). OBJECTIVE We aimed to systematically evaluate the most recent evidence on the feasibility and accessibility of telemedicine services, patients’ and care providers’ satisfaction with these services, and treatment outcomes related to telemedicine service use among pediatric populations with different health conditions. METHODS Studies were obtained from the PubMed database on May 10, 2020. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. In this review, we included randomized controlled trials from the last 10 years that used a telemedicine approach as a study intervention or assessed telemedicine as a subspecialty of pediatric care. Titles and abstracts were independently screened based on the eligibility criteria. Afterward, full texts were retrieved and independently screened based on the eligibility criteria. A standardized form was used to extract the following data: publication title, first author’s name, publication year, participants’ characteristics, study design, the technology-based approach that was used, intervention characteristics, study goals, and study findings. RESULTS In total, 11 articles met the inclusion criteria and were included in this review. All studies were categorized as randomized controlled trials (8/11, 73%) or cluster randomized trials (3/11, 27%). The number of participants in each study ranged from 22 to 400. The health conditions that were assessed included obesity (3/11, 27%), asthma (2/11, 18%), mental health conditions (1/11, 9%), otitis media (1/11, 9%), skin conditions (1/11, 9%), type 1 diabetes (1/11, 9%), attention deficit hyperactivity disorder (1/11, 9%), and cystic fibrosis–related pancreatic insufficiency (1/11). The telemedicine approaches that were used included patient and doctor videoconferencing visits (5/11, 45%), smartphone-based interventions (3/11, 27%), telephone counseling (2/11, 18%), and telemedicine-based screening visits (1/11, 9%). The telemedicine interventions in all included studies resulted in outcomes that were comparable to or better than the outcomes of control groups. These outcomes were related to symptom management, quality of life, satisfaction, medication adherence, visit completion rates, and disease progression. CONCLUSIONS Although more research is needed, the evidence from this review suggests that telemedicine services for the general public and pediatric care are comparable to or better than in-person services. Patients, health care professionals, and caregivers may benefit from using both telemedicine services and traditional, in-person health care services. To maximize the potential of telemedicine, future research should focus on improving patients’ access to care, increasing the cost-effectiveness of telemedicine services, and eliminating barriers to telemedicine use.

ACS Style

Aashaka C Shah; Sherif M Badawy. Telemedicine in Pediatrics: Systematic Review of Randomized Controlled Trials (Preprint). 2020, 1 .

AMA Style

Aashaka C Shah, Sherif M Badawy. Telemedicine in Pediatrics: Systematic Review of Randomized Controlled Trials (Preprint). . 2020; ():1.

Chicago/Turabian Style

Aashaka C Shah; Sherif M Badawy. 2020. "Telemedicine in Pediatrics: Systematic Review of Randomized Controlled Trials (Preprint)." , no. : 1.

Journal article
Published: 12 October 2020 in JMIR Pediatrics and Parenting
Reads 0
Downloads 0

School closures, altered access to health services, and economic stress during the COVID-19 pandemic have likely had an impact on the mental and physical well-being of youth worldwide, particularly among those with chronic health conditions (CHCs). A number of challenges and opportunities have emerged during the COVID-19 pandemic for youth with CHCs. Challenges include heightened anxiety, disrupted routines, academic and social stresses associated with school closure, increased risk of domestic violence and abuse, and reduced access to physical and psychosocial support. On the other hand, opportunities include reduced academic and social stress, increased time with families, reduced access to substances, easier access to health care using technology, and opportunities to build resilience. This viewpoint paper highlights both challenges and opportunities for youth with CHCs during the pandemic and offers recommendations for further research and clinical care.

ACS Style

Anna Serlachius; Sherif M Badawy; Hiran Thabrew. Psychosocial Challenges and Opportunities for Youth With Chronic Health Conditions During the COVID-19 Pandemic. JMIR Pediatrics and Parenting 2020, 3, e23057 .

AMA Style

Anna Serlachius, Sherif M Badawy, Hiran Thabrew. Psychosocial Challenges and Opportunities for Youth With Chronic Health Conditions During the COVID-19 Pandemic. JMIR Pediatrics and Parenting. 2020; 3 (2):e23057.

Chicago/Turabian Style

Anna Serlachius; Sherif M Badawy; Hiran Thabrew. 2020. "Psychosocial Challenges and Opportunities for Youth With Chronic Health Conditions During the COVID-19 Pandemic." JMIR Pediatrics and Parenting 3, no. 2: e23057.

Preprint content
Published: 08 October 2020
Reads 0
Downloads 0

BACKGROUND Suboptimal adherence to 6-mercaptopurine (6-MP) is prevalent in pediatric acute lymphoblastic leukemia (ALL) and associated with increased risk of relapse. Rapid uptake of personal technology makes mobile health (mHealth) an attractive platform to promote adherence. OBJECTIVE Study objectives were to examine access to mobile technology and preferences for an mHealth intervention to improve medication adherence in pediatric ALL. METHODS A cross-sectional survey was administered in oncology clinic to parents of children with ALL as well as adolescents and young adults (AYAs) with ALL receiving maintenance chemotherapy. RESULTS A total of 49 parents (median age [IQR] 39 [33-42] years; female 76% [37/49]) and 15 patients (median age [IQR] 17 [16-19]; male 80% [12/15]) participated. All parents and AYAs owned electronic tablets, smartphones, or both. Parents’ most endorsed mHealth app features included a list of medications (71%, 35/49), information about 6-MP (71%, 35/49), refill reminders (71%, 35/49), and reminders to take 6-MP (71%, 35/49). AYAs' most endorsed features included refill reminders (73%, 11/15), reminders to take 6-MP (73%, 11/15), and tracking 6-MP (73%, 11/15). CONCLUSIONS Parents and AYAs reported ubiquitous access to mobile technology and strong interest in multiple adherence-specific mHealth app features. Parents and AYAs provided valuable insight into preferred features for a multifunctional behavioral intervention (mHealth app) to promote medication adherence in pediatric ALL.

ACS Style

Mallorie B Heneghan; Tasmeen Hussain; Leonardo Barrera; Stephanie W Cai; Maureen Haugen; Elaine Morgan; Jenna Rossoff; Joanna Weinstein; Nobuko Hijiya; David Cella; Sherif M Badawy. Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques (Preprint). 2020, 1 .

AMA Style

Mallorie B Heneghan, Tasmeen Hussain, Leonardo Barrera, Stephanie W Cai, Maureen Haugen, Elaine Morgan, Jenna Rossoff, Joanna Weinstein, Nobuko Hijiya, David Cella, Sherif M Badawy. Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques (Preprint). . 2020; ():1.

Chicago/Turabian Style

Mallorie B Heneghan; Tasmeen Hussain; Leonardo Barrera; Stephanie W Cai; Maureen Haugen; Elaine Morgan; Jenna Rossoff; Joanna Weinstein; Nobuko Hijiya; David Cella; Sherif M Badawy. 2020. "Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques (Preprint)." , no. : 1.

Preprint content
Published: 30 July 2020
Reads 0
Downloads 0

UNSTRUCTURED School closures, altered access to health services, and economic stress during the COVID-19 pandemic have likely had an impact on the mental and physical well-being of youth worldwide, particularly among those with chronic health conditions (CHCs). A number of challenges and opportunities have emerged during the COVID-19 pandemic for youth with CHCs. Challenges include heightened anxiety, disrupted routines, academic and social stresses associated with school closure, increased risk of domestic violence and abuse, and reduced access to physical and psychosocial support. On the other hand, opportunities include reduced academic and social stress, increased time with families, reduced access to substances, easier access to health care using technology, and opportunities to build resilience. This viewpoint paper highlights both challenges and opportunities for youth with CHCs during the pandemic and offers recommendations for further research and clinical care.

ACS Style

Anna Serlachius; Sherif M Badawy; Hiran Thabrew. Psychosocial Challenges and Opportunities for Youth With Chronic Health Conditions During the COVID-19 Pandemic (Preprint). 2020, 1 .

AMA Style

Anna Serlachius, Sherif M Badawy, Hiran Thabrew. Psychosocial Challenges and Opportunities for Youth With Chronic Health Conditions During the COVID-19 Pandemic (Preprint). . 2020; ():1.

Chicago/Turabian Style

Anna Serlachius; Sherif M Badawy; Hiran Thabrew. 2020. "Psychosocial Challenges and Opportunities for Youth With Chronic Health Conditions During the COVID-19 Pandemic (Preprint)." , no. : 1.